Grufity logo
Grufity logo
CYCN

CYCN - Cyclerion Therapeutics Inc Stock Price, Fair Value and News

$31.91+7.97 (+33.29%)
Market Closed as of 11 Sep 2026, 03:59 pm ET

CYCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCN Price Action

Last 7 days

685.0%

Last 30 days

738.0%

Last 90 days

898.3%

Trailing 12 Months

1144.8%

CYCN RSI Chart

CYCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCN Valuation

Market Cap

103.7M

Price/Earnings (Trailing)

-19.65

Price/Sales (Trailing)

7.52

EV/EBITDA

-3.62

Price/Free Cashflow

-4.43

CYCN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYCN Fundamentals

CYCN Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

-22.83%

Rev. Growth (Qtr)

17.14%

CYCN Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

-122.32%

Earnings Growth (Qtr)

-297.62%

CYCN Profitability

EBT Margin

-170.11%

Return on Equity

-77.69%

Return on Assets

-62.03%

Free Cashflow Yield

-22.59%

CYCN Investor Care

Shares Dilution (1Y)

34.90%

Diluted EPS (TTM)

-1.33

Revenue & Growth

How Cyclerion Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20252.0M2.0M2.1M2.1M
20241.1M1.4M1.7M2.0M
2023--580.8K864.7K
20224.6M1.9M1.6M297.0K
20212.7M3.1M3.5M3.9M
20204.0M3.4M2.8M2.3M
2019---4.5M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cyclerion Therapeutics Inc

CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEcyclerion.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Cyclerion Therapeutics Inc Frequently Asked Questions

CYCN is the stock ticker symbol of Cyclerion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Sep 08 2026, market cap of Cyclerion Therapeutics Inc is 103.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Sep 08 2026, CYCN's PE ratio (Price to Earnings) is -19.65 and Price to Sales (PS) ratio is 7.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCN PE ratio will change depending on the future growth rate expectations of investors.